Literature DB >> 1382013

Newer neuromuscular blocking drugs. An overview of their clinical pharmacology and therapeutic use.

R K Mirakhur1.   

Abstract

Four new nondepolarising muscle relaxants, pipecuronium bromide, doxacurium chloride, mivacurium chloride and Org 9426 (rocuronium) offer alternatives to the established agents atracurium besilate and vecuronium bromide. Pipecuronium and Org 9426 are steroidal compounds, the latter being a monoquaternary agent, whereas doxacurium and mivacurium are bisquaternary benzylisoquinolinium compounds. Pipecuronium and doxacurium have a relatively slow onset and a long duration of action. Pipecuronium produces maximum block in 3 to 6 min when given in a dose of 45 to 80 micrograms/kg, and a duration of clinical relaxation of between 40 and 110 min. Doxacurium is more potent, but is the least rapid and the longest acting relaxant currently available. When administered in doses of 37 to 80 micrograms/kg, it produces maximum block within 3.5 to 10 min, with a duration of clinical relaxation of 77 to 164 min. The advantage of both pipecuronium and doxacurium is their cardiovascular stability. Both agents are primarily eliminated via the kidneys and both have now been licensed for use in the US. Mivacurium is a muscle relaxant with a short duration of action. When administered in doses of 0.1 to 0.25 mg/kg it produces maximum block in 2 to 4 min, but the duration of clinical relaxation is less than 20 min. Higher doses which could induce a faster neuromuscular block are unfortunately associated with some histamine liberation. The drug is metabolised by plasma cholinesterase. Mivacurium has also been licensed for use in the US. Org 9426 is an agent with a rapid onset but an intermediate duration of action. A dose of 0.5 to 0.6 mg/kg induces maximum block in about 1.5 min and has a duration of clinical relaxation of about 30 min. The rapid onset of effect could be useful for early intubation as an alternative to suxamethonium chloride. However, much more clinical experience is needed with this agent, particularly with regard to duration of action of larger doses and occurrence of side effects. The drug is mainly eliminated via the liver.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1382013     DOI: 10.2165/00003495-199244020-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  71 in total

1.  The neuromuscular blocking effect of Org 9426. A new intermediately-acting steroidal non-depolarising muscle relaxant in man.

Authors:  L H Booij; H T Knape
Journal:  Anaesthesia       Date:  1991-05       Impact factor: 6.955

2.  The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl.

Authors:  J M Wierda; U W Kleef; L M Lambalk; W D Kloppenburg; S Agoston
Journal:  Can J Anaesth       Date:  1991-05       Impact factor: 5.063

3.  The clinical neuromuscular pharmacology of mivacurium chloride (BW B1090U). A short-acting nondepolarizing ester neuromuscular blocking drug.

Authors:  J J Savarese; H H Ali; S J Basta; P B Embree; R P Scott; N Sunder; J N Weakly; W B Wastila; H A el-Sayad
Journal:  Anesthesiology       Date:  1988-05       Impact factor: 7.892

4.  Clinical pharmacology of doxacurium chloride (BW A938U) in children.

Authors:  J B Sarner; B W Brandom; D R Cook; M L Dong; M C Horn; S K Woelfel; P J Davis; G D Rudd; V J Foster; B F McNulty
Journal:  Anesth Analg       Date:  1988-04       Impact factor: 5.108

5.  Transient systemic arterial hypotension and cutaneous flushing in response to doxacurium chloride.

Authors:  D L Reich
Journal:  Anesthesiology       Date:  1989-11       Impact factor: 7.892

6.  Clinical experiences with pipecuronium bromide.

Authors:  M Boros; J Szenohradszky; A Kertész; G Marosi; L Tutsek
Journal:  Acta Chir Hung       Date:  1983

7.  Interaction of antibiotics on pipecuronium-induced neuromuscular blockade.

Authors:  N E de Gouw; J F Crul; E Vandermeersch; J P Mulier; J van Egmond; H Van Aken
Journal:  J Clin Anesth       Date:  1993 May-Jun       Impact factor: 9.452

8.  Comparative clinical study of pipecurium bromide and pancuronium bromide.

Authors:  M Boros; J Szenohradszky; G Marosi; I Tóth
Journal:  Arzneimittelforschung       Date:  1980

9.  Antagonism of vecuronium by one of its metabolites in vitro.

Authors:  K S Khuenl-Brady; P Mair; J Koller
Journal:  Eur J Pharmacol       Date:  1992-11-03       Impact factor: 4.432

10.  Clinical pharmacology of mivacurium chloride (BW B1090U) in children during nitrous oxide-halothane and nitrous oxide-narcotic anesthesia.

Authors:  J B Sarner; B W Brandom; S K Woelfel; M L Dong; M C Horn; D R Cook; B F McNulty; V J Foster
Journal:  Anesth Analg       Date:  1989-02       Impact factor: 5.108

View more
  8 in total

1.  Full-cost determination of different levels of care in the intensive care unit. An activity-based costing approach.

Authors:  J J Doyle; J P Casciano; S R Arikian; J Mauskopf; J E Paul
Journal:  Pharmacoeconomics       Date:  1996-10       Impact factor: 4.981

Review 2.  Anesthesia.

Authors:  J Appleby; V A Lawrence
Journal:  J Gen Intern Med       Date:  1994-11       Impact factor: 5.128

3.  Haemodynamic effects of rocuronium during fentanyl anaesthesia: comparison with vecuronium.

Authors:  E P McCoy; V R Maddineni; P Elliott; R K Mirakhur; I W Carson; R A Cooper
Journal:  Can J Anaesth       Date:  1993-08       Impact factor: 5.063

Review 4.  Mivacurium. A review of its pharmacology and therapeutic potential in general anaesthesia.

Authors:  James E Frampton; Donna McTavish
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

Review 5.  [Fast-track rehabilitation in colon surgery. Contribution of anesthesia].

Authors:  T Möllhoff; H-J Kress; K Tsompanidis; C Wolf; P Ploum
Journal:  Anaesthesist       Date:  2007-07       Impact factor: 1.041

6.  Potentiation of Rocuronium Bromide by Lithium Carbonate: A Case Report.

Authors:  Naotaka Kishimoto; Hiroyuki Yoshikawa; Kenji Seo
Journal:  Anesth Prog       Date:  2020-09-01

Review 7.  Pharmacology, selection and complications associated with neuromuscular blocking drugs in ICU patients.

Authors:  R C Prielipp
Journal:  Yale J Biol Med       Date:  1998 Nov-Dec

Review 8.  New developments in nondepolarizing muscle relaxants.

Authors:  R K Mirakhur
Journal:  Yale J Biol Med       Date:  1993 Sep-Oct
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.